Navigation Links
New Data Support Use of Simple Test to Predict Endometrial Cancer Response to Chemotherapy
Date:6/1/2009

Study Presented at 2009 American Society of Clinical Oncologist Annual Meeting

ORLANDO, Fla., June 1 /PRNewswire/ -- New data presented today at the 2009 American Society of Clinical Oncologist (ASCO) Annual Meeting support the use of a laboratory test, ChemoFX(R), to help physicians predetermine the effectiveness of chemotherapy in treating a woman's endometrial cancer. Investigators found a significant correlation between the test results from 405 patient specimens analyzed using ChemoFx and published patient response rates for each chemotherapeutic regimen, suggesting less effective therapies could be eliminated prior to patient administration. Endometrial cancer is the most common gynecologic cancer among women in the United States.

"Limiting a patient's exposure to chemotherapy is important, however determining the appropriate treatment the first time for a woman with endometrial cancer can be challenging," said Dr. Warner K. Huh, MD., Lead Investigator and Associate Professor, Division of Gynecologic Oncology, University of Alabama at Birmingham, "These data suggest a more targeted approach could be achieved by testing the effect of various chemotherapeutic agents on a woman's tumor before a therapy is administered to the patient, potentially bypassing use of ineffective therapies."

Published data suggest that individual patients will only respond to a single chemotherapy agent 30 percent of the time and while combination therapy can increase a patient's response up to 60 percent, finding the combination that will achieve that response can prove difficult. The unintended consequences of ineffective treatment include, but are not limited to, patient exposure to the toxic aspects of the chemotherapy and delay in the patient receiving potentially beneficial treatments. ChemoFx is a test that quantifies an individual cancer patient's probable tumor response to various chemotherapeutic
'/>"/>

SOURCE Precision Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Wyeth Donates $100,000 to ASCO Cancer Foundation(R) to Support Cancer Prevention and Care
2. Global Creative, Media and Technology Agency LBi Launches Cutting Edge Social Movement for the British Red Cross in Support of Refugee Week
3. Prairie Island Indian Community Supports Fight Against Diabetes Locally and Nationally
4. Concurrent Technologies Corporation Awarded Contract to Support the Centers for Disease Control and Prevention with Readiness Efforts
5. New Virginia Poll: 71 Percent of Voters Strongly Support FDA Regulation of Tobacco Products
6. New Mississippi Poll: Voters Strongly Support FDA Regulation of Tobacco Products
7. Craneware Supports Hospitals Compliance and Upfront Collections with Accurate Estimates
8. Spanish-Speaking OmniPod Customer Support Now Available Around-the-Clock
9. Voters Urged to Support Budding Moves to Include Long Term Care in National Health Reform
10. Kindred Healthcare Supports the Flag and the Sacrifices it Represents
11. Childrens Health Fund Receives $500,000 from the Starr International Foundation to Support South Bronx Homeless Health Care Clinic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... ... La Jolla, Calif. (Vocus) -- The physicians at Scripps ... new chief of staff of the 372-bed facility. Dr. Sedwitz will ... 1, 2010. , , , , ,During his two-year term, Dr. ... administrative staff and its board of directors. Dr. Sedwitz will play ...
(Date:12/14/2009)... ,, NEW YORK, Dec. 14 /PRNewswire-USNewswire/ -- ... -- the largest survey on teen drug abuse tracking ... that teens, intentional abuse of prescription (Rx) and over-the-counter ... with an alarming number of young people abusing medicines ... Teen Abuse of Medication Continues to Be a ...
(Date:12/14/2009)... The Hemophilia Federation of America (HFA) expresses its ... Teamsters Local 929 and the American Red Cross ... depends on skilled workers to provide clean, safe ... products such as clotting factor for use in ... The Division of Blood Services at the American ...
(Date:12/14/2009)... men whose disease had been treated, hadn,t spread, study ... appears to reduce the risk of death in male ... began in January 1986, included 668 men who,d been ... colon cancer that had not spread (nonmetastatic cancer). Every ... them about any new cancer and disease diagnoses, as ...
(Date:12/14/2009)... study finds, , , MONDAY, Dec. 14 (HealthDay News) -- ... morning without a cup or two of java: Coffee ... type 2 diabetes. , That,s the conclusion of ... you drink, the lower your risk of diabetes. Every ... reduction in the risk of diabetes, the researchers said. ...
Breaking Medicine News(10 mins):Health News:New Chief of Staff Takes Over at Scripps Memorial Hospital La Jolla 2Health News:New Chief of Staff Takes Over at Scripps Memorial Hospital La Jolla 3Health News:Partnership for a Drug-Free America(R) Responds to 2009 Monitoring the Future Study Results 2Health News:Partnership for a Drug-Free America(R) Responds to 2009 Monitoring the Future Study Results 3Health News:HFA Voices Blood Safety Concerns 2Health News:Physical Activity May Prolong Survival After Colon Cancer 2Health News:Coffee, Tea Might Stave Off Diabetes 2Health News:Coffee, Tea Might Stave Off Diabetes 3
... maintain strength, not gain it, while you mend , , WEDNESDAY, ... fitness enthusiast who suffers a strained muscle, sprained ankle or ... , "Exercise can definitely be beneficial for a person dealing ... should be moved and not left in place for a ...
... April 23 Speaker Nancy Pelosi,spoke at the Congressional ... renowned heart surgeon Dr. Michael DeBakey. Below are the,Speaker,s ... indeed to join President Bush,leaders of the House and ... commend Senator Hutchison and my colleague Representative Al,Green, and ...
... 23 Global leaders are,rediscovering the importance of ... for competing in today,s economic,environment, according to a ... study further reveals -- Competitive Intelligence adds value ... raw competitive data,into actionable insights that have a ...
... (EGPAF), a world leader in the fight against pediatric ... $1 million to researchers to support the development of ... PhD, professor of medicine at the University of Massachusetts ... MD, professor of pediatrics and director of the division ...
... and Industry Directions Launch New Study, FALLS ... and Industry Directions Inc., in close,association with research ... to respond to a new survey on current ... objectives,business processes and practices, information systems and applications, ...
... Blocking IL-11 protein prevents inflammation, hints of new treatments ... Scientists say they may have discovered how tumors develop ... new treatments for gastric cancer. , In a study ... the International Ludwig Institute for Cancer Research (LICR) found ...
Other Medicine News:Health News:Exercise Plays Role in Recovery From Sports Injuries 2Health News:Pelosi: 'By Literally Fixing Broken Hearts, Dr. DeBakey Has Given Hope and Health to Millions' 2Health News:Complimentary Excerpt Available from Best Practices: Pharmaceutical Competitive Intelligence Excellence - Optimizing Data Collection within Approved Guidelines 2Health News:UMass Medical School researchers awarded pediatric HIV vaccine development grant 2Health News:UMass Medical School researchers awarded pediatric HIV vaccine development grant 3Health News:Risk Management: Best Practices for Medical Device Profitability 2Health News:Scientists Discover How Stomach Tumors Form 2
(Date:12/14/2009)... Dec. 14 Watson Pharmaceuticals, Inc. (NYSE: ... program encouraging health professionals to help maintain the ... on long-term androgen deprivation therapy (ADT). Nearly ... treatment for prostate cancer that, while highly effective ... loss and increase a man,s risk for osteoporosis. ...
(Date:12/14/2009)... Ohr Pharmaceutical Inc. (OTC Bulletin Board: OHRP) ... Inc, headquartered in Irvine, CA, with offices also ... for investor relations and corporate communications. Ohr ... on developing advanced drugs for underserved therapeutic needs. ... large, global markets: OHR/AVR118 for the treatment of ...
(Date:12/14/2009)... Calif. and REHOVOT, Israel, Dec. 14 ... technology and services resource for pathologists, oncologists and ... today jointly announced that they will collaborate on ... non-invasive test for the early detection of non-small ... patient,s sputum and was originally developed at the ...
Breaking Medicine Technology:Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy 2Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy 3Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy 4Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy 5Ohr Pharmaceutical Selects Allen & Caron for Investor Relations, Corporate Communications 2Ohr Pharmaceutical Selects Allen & Caron for Investor Relations, Corporate Communications 3Clarient, BioView Initiate Alliance to Finalize Development and Commercialize Non-Invasive Molecular Diagnostic Test for Early Detection of Lung Cancer 2Clarient, BioView Initiate Alliance to Finalize Development and Commercialize Non-Invasive Molecular Diagnostic Test for Early Detection of Lung Cancer 3Clarient, BioView Initiate Alliance to Finalize Development and Commercialize Non-Invasive Molecular Diagnostic Test for Early Detection of Lung Cancer 4New Online Tutorials for Madeline 2 0 and CGAP from OpenHelix 54603 1New Online Tutorials for Madeline 2 0 and CGAP from OpenHelix 54603 2New Online Tutorials for Madeline 2 0 and CGAP from OpenHelix 54603 3AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia 13582 1AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia 13582 2AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia 13582 3AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia 13582 4AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia 13582 5AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia 13582 6AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia 13582 7US FDA Approves Extavia 28R 29 the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease 4853 1US FDA Approves Extavia 28R 29 the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease 4853 2US FDA Approves Extavia 28R 29 the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease 4853 3US FDA Approves Extavia 28R 29 the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease 4853 4US FDA Approves Extavia 28R 29 the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease 4853 5US FDA Approves Extavia 28R 29 the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease 4853 6US FDA Approves Extavia 28R 29 the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease 4853 7
... Mass., April 3, 2008 Thermo Fisher,Scientific Inc. ... serving science, announced,that it has received U.S. Food ... test designed to screen for methicillin-resistant,Staphylococcus aureus (MRSA), ... Positive Predictive Value commercially available for MRSA,screening, Spectra ...
... N.J., April 3, 2008 Medarex, Inc.,(Nasdaq: ... statement in response to the,announcement by Pfizer ... 3 clinical,trial of front-line treatment with Pfizer,s ... patients with advanced,melanoma. Dr. Geoffrey M. Nichol, ...
Other Medicine Technology:Thermo Fisher Scientific Receives FDA Clearance for MRSA Test Medium 2Thermo Fisher Scientific Receives FDA Clearance for MRSA Test Medium 3Thermo Fisher Scientific Receives FDA Clearance for MRSA Test Medium 4Medarex Announces Ipilimumab Program Continues to Move Forward 2Medarex Announces Ipilimumab Program Continues to Move Forward 3Medarex Announces Ipilimumab Program Continues to Move Forward 4Medarex Announces Ipilimumab Program Continues to Move Forward 5
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: